Composition for preventing or treating neurodegenerative disease
AssigneeKyoto University
InventorsHaruhisa Inoue, Koh Ono, Keiko Imamura, Takahiro Horie, Fumiko Nakazeki
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.
Claims3
A miR-33a function inhibitor comprising, as an active ingredient, an antisense oligonucleotide that consists of a nucleotide sequence set forth in SEQ ID NO:
- 24, and wherein each internucleotide bond in the nucleotide sequence is a phosphorothioate bond.
A composition for treating hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, an antisense oligonucleotide that consists of a nucleotide sequence set forth in SEQ ID NO:
- 24, and wherein each internucleotide bond in the nucleotide sequence is a phosphorothioate bond.
A method for treating hereditary spastic paraplegia SPG4, the method comprising administering to a subject an antisense oligonucleotide that consists of a nucleotide sequence set forth in SEQ ID NO:
- 24 wherein each internucleotide bond in the nucleotide sequence is a phosphorothioate bond.
Dependencies are inferred from the claim text.